These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 30900874)

  • 21. Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine.
    Balamane M; Varghese V; Melikian GL; Fessel WJ; Katzenstein DA; Shafer RW
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4522-4. PubMed ID: 22664973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants.
    Smith SJ; Pauly GT; Akram A; Melody K; Ambrose Z; Schneider JP; Hughes SH
    J Acquir Immune Defic Syndr; 2016 Aug; 72(5):485-91. PubMed ID: 27124362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function.
    Xu HT; Oliveira M; Quan Y; Bar-Magen T; Wainberg MA
    J Antimicrob Chemother; 2010 Nov; 65(11):2291-9. PubMed ID: 20852269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
    Gatanaga H; Ode H; Hachiya A; Hayashida T; Sato H; Oka S
    Antimicrob Agents Chemother; 2010 Apr; 54(4):1596-602. PubMed ID: 20124001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple drugs and multiple targets: an analysis of the electrostatic determinants of binding between non-nucleoside HIV-1 reverse transcriptase inhibitors and variants of HIV-1 RT.
    Minkara MS; Davis PH; Radhakrishnan ML
    Proteins; 2012 Feb; 80(2):573-90. PubMed ID: 22095671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dead-end complexes contribute to the synergistic inhibition of HIV-1 RT by the combination of rilpivirine, emtricitabine, and tenofovir.
    Kulkarni R; Feng JY; Miller MD; White KL
    Antiviral Res; 2014 Jan; 101():131-5. PubMed ID: 24291780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanism of HIV reverse transcriptase inhibition by zinc: formation of a highly stable enzyme-(primer-template) complex with profoundly diminished catalytic activity.
    Fenstermacher KJ; DeStefano JJ
    J Biol Chem; 2011 Nov; 286(47):40433-42. PubMed ID: 21953456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.
    Namasivayam V; Vanangamudi M; Kramer VG; Kurup S; Zhan P; Liu X; Kongsted J; Byrareddy SN
    J Med Chem; 2019 May; 62(10):4851-4883. PubMed ID: 30516990
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efavirenz accelerates HIV-1 reverse transcriptase ribonuclease H cleavage, leading to diminished zidovudine excision.
    Radzio J; Sluis-Cremer N
    Mol Pharmacol; 2008 Feb; 73(2):601-6. PubMed ID: 18024510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular Docking Studies and Synthesis of Amino-oxy-diarylquinoline Derivatives as Potent Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors.
    Makarasen A; Kuno M; Patnin S; Reukngam N; Khlaychan P; Deeyohe S; Intachote P; Saimanee B; Sengsai S; Boonsri P; Chaivisuthangkura A; Sirithana W; Techasakul S
    Drug Res (Stuttg); 2019 Dec; 69(12):671-682. PubMed ID: 31698495
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and its inhibition by efavirenz.
    Crespan E; Locatelli GA; Cancio R; Hübscher U; Spadari S; Maga G
    Antimicrob Agents Chemother; 2005 Jan; 49(1):342-9. PubMed ID: 15616314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efavirenz binding site in HIV-1 reverse transcriptase monomers.
    Braz VA; Barkley MD; Jockusch RA; Wintrode PL
    Biochemistry; 2010 Dec; 49(49):10565-73. PubMed ID: 21090588
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine.
    Alcaro S; Alteri C; Artese A; Ceccherini-Silberstein F; Costa G; Ortuso F; Bertoli A; Forbici F; Santoro MM; Parrotta L; Flandre P; Masquelier B; Descamps D; Calvez V; Marcelin AG; Perno CF; Sing T; Svicher V
    ChemMedChem; 2011 Dec; 6(12):2203-13. PubMed ID: 21953939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
    Bannister WP; Ruiz L; Cozzi-Lepri A; Mocroft A; Kirk O; Staszewski S; Loveday C; Karlsson A; Monforte Ad; Clotet B; Lundgren JD;
    AIDS; 2008 Jan; 22(3):367-76. PubMed ID: 18195563
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 96-Week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials.
    Rimsky L; Van Eygen V; Hoogstoel A; Stevens M; Boven K; Picchio G; Vingerhoets J
    Antivir Ther; 2013; 18(8):967-77. PubMed ID: 23714781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
    Lai MT; Munshi V; Touch S; Tynebor RM; Tucker TJ; McKenna PM; Williams TM; DiStefano DJ; Hazuda DJ; Miller MD
    Antimicrob Agents Chemother; 2009 Jun; 53(6):2424-31. PubMed ID: 19289522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies.
    Anta L; Llibre JM; Poveda E; Blanco JL; Alvarez M; Pérez-Elías MJ; Aguilera A; Caballero E; Soriano V; de Mendoza C;
    AIDS; 2013 Jan; 27(1):81-5. PubMed ID: 22842995
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase.
    Ren J; Milton J; Weaver KL; Short SA; Stuart DI; Stammers DK
    Structure; 2000 Oct; 8(10):1089-94. PubMed ID: 11080630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanistic Study of Common Non-Nucleoside Reverse Transcriptase Inhibitor-Resistant Mutations with K103N and Y181C Substitutions.
    Lai MT; Munshi V; Lu M; Feng M; Hrin-Solt R; McKenna PM; Hazuda DJ; Miller MD
    Viruses; 2016 Sep; 8(10):. PubMed ID: 27669286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.
    Reuman EC; Rhee SY; Holmes SP; Shafer RW
    J Antimicrob Chemother; 2010 Jul; 65(7):1477-85. PubMed ID: 20462946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.